未名醫藥(002581.SZ)延期回覆深交所關注函
格隆匯2月3日丨未名醫藥(002581.SZ)公佈,格式於2020年1月20日收到深圳證券交易所出具的《關於對山東未名生物醫藥股份有限公司的關注函》(中小板關注函【2020】第58號),要求公司在2020年1月31日前完成關注函有關説明材料的回覆和披露工作,同時抄報山東證監局上市公司監管處。
公司收到關注函後,積極組織各相關方及中介機構共同對關注函中涉及的問題進行逐項落實和回覆。因受新型冠狀病毒疫情影響,公司及各中介機構工作時間延後,以致無法按原預計時間完成回覆和披露工作,為確保信息披露內容的真實、準確、完整,經申請,公司對此次關注函延期回覆。公司將加快進度,儘快回覆。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.